CHM Cannabis
Home > Boards > US Listed > Biotechs >

Oncolytics Biotech Inc. (ONCYD)

Add ONCYD Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 6/6/2018 1:23:54 AM - Followers: 81 - Board type: Free - Posts Today: 0


Oncolytics Biotech, Inc.
Technology Changing Life

Dr Brad Thompson - CEO Oncolytics Biotech                                    Dr Matt Coffey
Dr. Brad Thompson, COB, President and CEO                                2008 Photo of Dr Matt Coffey - COO

Photograph by:  Gavin Young, Calgary Herald


A Novel Approach to Cancer Therapeutics

Oncolytics Biotech is a biotechnology company focused on the development of oncolytic viruses as potential therapeutics for use in a broad range of cancers. The Company is conducting clinical studies using REOLYSIN®, its proprietary formulation of the human reovirus, in some of the most prevalent forms of the disease including lung, colorectal and pancreatic cancers. Oncolytics' clinical program includes a number of human trials at a variety of stages including a Phase III trial in head and neck cancers. The Company has advanced its product manufacturing and intellectual property initiatives in parallel with its clinical development program to support development of a commercial product.

See the official company website for the most current information.   www.oncolyticsbiotech.com

CURRENT SUMMARY - March 9th 2014

Expanding Clinical Program 
o Lead product is REOLYSIN®, a broadly active novel cancer therapy 
o Ongoing clinical trials include seven randomized studies
o Enrollment complete randomized international study (REO 018) of  REOLYSIN® in combination with carboplatin and
paclitaxel in platinum- refractory recurrent head and neck cancer patients – the supportive 
study to a planned Phase III registration study in this indication 
o Six sponsored Phase II studies announced or ongoing in the US and 
Canada – breast, non-small cell lung, colorectal, prostate, pancreatic 
and ovarian cancers 
o Strong Intellectual Property Portfolio 
o More than 370 patents issued worldwide
o Manufacturing at Commercial Scale  - 100L cGMP completed, commercial manufacturing agreement in place 


REOLYSIN is a proprietary isolate of the reovirus
Reovirus is a replication competent virus and is considered safe to humans
REOLYSIN has been safely administered to patients via intravenous, intratumoral and intrathecal injection
Mechanism of Action:
In Ras-activated cells, one of the key cellular defence mechanisms against double-stranded RNA viral infection, Protein Kinase-R (PKR), is deactivated
This specific vulnerability of constitutive Ras-activated cancer cells to the reovirus is the basis of REOLYSIN's activity and specificity
Reovirus oncolysis is seen in cancer cells with constitute Ras pathway activation; susceptible cancer cells therefore include those with either:
EGFR overexpression or mutation1; or
Ras mutation, which includes Kras mutation2
Both of these mutations lead to activation of the Ras pathway

  1. Results from the NCI sponsored PH II Pancreatic Cancer trial ... Principal Investigator: Tanois Bekaii-Saab: 
    Data publication of the Phase III H&N : PFS data from the first 160 patients - REO 018, the Phase III SCCHN Trial data now separated into two distinct sub groups... "local recurrent disease, with or without metastases, and patients with distal metastases"   -  >Recruiting completed in the US, Canada, Belgium, UK. Italy, Spain, and Russia.  See November 21 2013 press release describing preliminary results of the first sub group.  See Sept 12 2012 press release regarding the analysis of unblinded data from the first 80 patients.   "The Company has consulted with its principal investigators and the independent statistician for the study, and, on September 10, 2012, met with the U.S. Food and Drug Administration in Washington, D.C. Based on these discussions, the Company plans to expand enrollment in the first stage of the study to include 160 patients, all of whom have now been enrolled.  Oncolytics intends to treat this expanded first stage of the REO 018 clinical trial as a separate supportive study to a planned registration study that will be similar to, and take the place of, the original second stage of the REO 018 clinical trial."  
    Principal Investigators Jan Vermorken - Belgium Dr. Jan Vermorken Dr Kevin Harrington - UK , Dr. James A Bonner - USDr James Bonner

    Publication of data for the PH I/II Ovarian cancer trial also sponsored by the NCI and conducted by Principal Investigator Dr. David Cohn 



  • 32 human clinical trials running or concluded
    Conducting multiple Phase I/II, Phase II REOLYSIN clinical trials in the United Kingdom and the United States and one Phase III .
    Positive interim and final data emerging including clinical responses in lung, liver and nodal metastatic disease
    Collaborative agreements with the National Cancer Institute of the US and the NCIC-CTG Canada, the University of Leeds, and the Cancer Therapy & Research Center at the University of Texas Health Science Center in the U.S. to conduct multiple clinical trials.
    The Gynecologic Oncology Group (GOG) is conducting a randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN® in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer (GOG186H).
    The Children's Oncology Group (COG) is conducting a Phase I trial of REOLYSIN® in combination with cyclophosphamide in pediatric patients with relapsed or refractory solid tumors.
    Strong IP position , Over 300 Patents Worldwide including 34 US Patents  - US Patents can be found at this link.
    Experienced management team and board of directors


The ubiquitous reovirus

Reovirus, an acronym for Respiratory Enteric Orphan virus, is generally believed to inhabit the respiratory and bowel systems in humans. Reovirus is found naturally in sewage and water supplies. By age 12, half of all children show evidence of reovirus exposure and by adulthood, most people have been exposed. However, the disease is non-pathogenic, meaning there are typically no symptoms from infections. The link to its cancer-killing ability was established after the reovirus was discovered to reproduce well in various cancer cell lines.


Using improved microscope technology, a team including Purdue's Timothy S. Baker and a colleague at Harvard has determined the structure of a reovirus (short for "respiratory enteric orphan" virus) down to the 7.6-angstrom scale, better than twice the 18-angstrom resolution previously available.  http://www.purdue.edu/UNS/html4ever/031215.Baker.reovirus.html




Synchrotron radiation is the only tool available for the determination of very large molecular structures at high resolution such as the reovirus core. One of the largest structures solved to-date has been reported from work carried out at MacCHESS by Karin Reinish in the Harrison group at Harvard. The reovirus core is a macromolecular assembly with a molecular mass of 52 million. The core synthesizes, modifies, and exports viral messenger RNA. The core contains five of the eight proteins that make up a complete virion and is about 700 Angstroms in diameter. They crystallize in a centered cubic space group with unit cell dimensions of 1255 Angstrom with crystal growth requiring 9 to 12 months. Using the CHESS F1 facility, one of the two Biosafety Level 2 facilities in the US, scientists have been able to "see" into the three-dimensional structure of the core using the tools of x-ray crystallography.

The reovirus core particle shows the subunits in different colors. There are 120 copies of the part in red that forms the shell and that packages the RNA. This part defines the symmetry and size of the particle. Other subunits, shown in yellow, green and white stabilize the shell. The blue parts form turret-like structures around the fivefold axes that exports mature mRNA into the cytoplasm of the infected cell.





is a proprietary variant of the human reovirus that acts primarily as a direct cytotoxic agent. Reovirus is naturally occurring (not genetically engineered) and has been demonstrated to replicate specifically in tumour cells bearing an activated Ras pathway, leaving healthy normal cells intact. At least two thirds of carcinomas and more than 90% of metastatic disease has Ras involvement.


Mechanism of Action


The reovirus, or Respiratory Enteric Orphan virus, has been demonstrated to replicate specifically in tumor cells that have a constitutively activated Ras pathway. Activating mutations of Ras and mutations along the Ras pathway occur in approximately two-thirds of all tumors. Tumors bearing an activated Ras pathway are deficient in their ability to activate an anti-viral response mediated by the host cellular protein, PKR. Since PKR is responsible for preventing reovirus replication, tumor cells that lack the activity of PKR are susceptible to reovirus infection and eventual cell death. As normal cells do not possess Ras activation, these cells are able to thwart reovirus infection by the activity of PKR. In a tumor cell with an activated Ras pathway, the reovirus is able to freely replicate and kill the host tumor cell. Progeny virus particles are then able to infect and kill surrounding cancer cells. This cycle of infection, replication and cell death is believed to be repeated until there are no longer any tumor cells carrying an activated Ras pathway available.

The Company's technologies are based on discoveries made in the 1990s in the Department of Microbiology and Infectious Diseases at the University of Calgary. The potential products are being developed using the naturally occurring reovirus for treatment of cancers in humans. 

The KRAS Opportunity

In mid-2009, the U.S. FDA approved revisions to labeling of the epidermal growth factor receptor (EGFR) class of antibodies, indicating that colorectal patients who have KRAS mutations in their tumours do not respond to EGFR-inhibiting antibodies and that the use of this class of pharmaceuticals is not recommended for these patients.

REOLYSIN, Oncolytics' proprietary isolate of the reovirus, preferentially replicates in cancer cells that have an activated RAS pathway. Approximately two-thirds of all cancers have an activated RAS pathway, including most metastatic disease. A large number of mutations, including mutations in EGFR, Her2 or KRAS along the RAS pathway lead to RAS pathway activation. A significant clinical opportunity for REOLYSIN is in the treatment of patients with metastatic cancers who have a mutated KRAS gene and are unlikely to respond to treatment with anit-EGFR monoclonal antibodies.


Current Clinical Trials Roadmap 

Company published list by Trial Number     http://www.oncolyticsbiotech.com/clinical.html

List of US based clinical trials on the official ClinicalTrials.gov website...Search Term: Reolysin

ist of EU based clinical trials on the official EU ....  


Key Published Scientific Data

Links collected here on the company website

Oncolytic Reovirus Effectively Targets Breast Cancer Stem Cells by Patrick Lee's lab published March 17, 2009 in Mol Therapy


DAILY and WEEKLY Stock Charts


Trading Data Share Structure

Exchange Symbol: TSX: ONC Estimated As at Jun, 2012
  NASDAQ: ONCY Outstanding:  76.6 million

***Cash On Hand Reported to be approx CAD $31.25 Mil on June 30th, 2012 including the bought deal of CAD $18+Mil conversion announced in Feb 2012.  Monthly Burn Rate has increased to $3.1 Mil - From Q2 2012  6mo Income Statement.  Current and Past Financials can be found by clicking here!

 - All numbers are stated in Canadian Dollars  



Curing Cancer? Patrick Lee's Path to the Reovirus Treatment 


by Paul Thagard from the Philosophy Department of Waterloo in 2002


lDalhousie virologist Patrick Lee: (Danny Abriel Photo)

Dalhousie virologist Patrick Lee:



REOLYSIN® is a proprietary variant of the reovirus, an acronym for Respiratory Enteric Orphan Virus, which is widely found in the environment. By adulthood, most people have been exposed to the reovirus. The reovirus is non-pathogenic, which means that infections are typically asymptomatic. In clinical trials, REOLYSIN® has been shown to be well-tolerated, with patients exhibiting only mild, flu-like symptoms. REOLYSIN® has been used alone and in combination with chemotherapy and radiotherapy for various cancers, including head and neck cancers in an ongoing Phase III clinical trial.


REOLYSIN® is based upon research conducted by the Chief Operating Officer of Oncolytics, Dr. Matt Coffey. It was found that the reovirus was able to infect and selectively destroy cancer cells. When a normal cell is infected with the reovirus, an antiviral response is activated, which prevents the virus from replicating within the cell. However, inside a cancer cell with one or more mutations on a growth pathway called the Ras pathway, there is an aberrant antiviral response that is unable to prevent the virus from replicating. This abnormality allows the reovirus to multiply to an extent that is fatal to the cancer cell.


You Tube Video On How Reolysin works        

------------Oncolytics Reolysin 2013 --------------Viral therapy delivers double blow to cancer ---------REOLYSIN® and Chemotherapy------------------------- REOLYSIN® and Radiotherapy----------------

Click on Image to watch You Tube Video

Breakthrough Therapies Target Cancers in 2015

Wed, 03/11/2015 - 8:57am

Getting a new drug to market is difficult, but the U.S. Food and Drug Administration (FDA) offers a number of ways to help the process along for promising drugs that have potential against serious diseases.  One of these options is designation as a breakthrough therapy. This year a number of these therapies are targeted at fighting cancer.
The breakthrough designation helps expedite the process for drug development and review for the treatment of serious or life-threatening conditions. According to the FDA, the criteria for breakthrough therapy designation require preliminary clinical evidence that demonstrates the drug may have substantial improvement on at least one clinically significant endpoint over available therapy.
During the fiscal year 2015, the FDA’s Center for Drug Evaluation and Research received 43 requests for breakthrough designation. Of these, six were granted and 13 were denied. The Center for Biologics Evaluation and Research granted three out of 10 requests for the same time period, and denied five. 

Testimonials on REOLYSIN® Cancer Treatment

Kenneth Scott visits with his wife, Helen, while receiving a REOLYSIN® cancer treatment.

I received this email today from Kenny. God is so good.
Hello, Deborah,
I apologize for not updating you recently. Things have been extremely busy for us, as you can understand. Throughout the last eight months, we have grown even more certain of several things: God loves us more than we could know…He has a plan for us…His plan is not only for His glory but for our good…God is in control! PRAISE HIM!
Since August, we have been going to San Antonio every four weeks for experimental treatments with Reolysin, a drug containing the virus called reovirus. Although I have experienced flu-like symptoms during each “treatment week”, I have tolerated it well with no real lasting side effects. I am feeling pretty good or better most of the time.
I have had CT scans just about every eight weeks during all of this. Each of the scans have looked virtually the same, meaning there are still tumors or masses there, but they appear to be unchanged (stable) over the past six months. However, this last time, I also had a PET scan (my first one). The results showed “no metabolic activity”, which “suggests” that there may not be any active cancer cells anywhere. Medically speaking, there seems to be little evidence that I have cancer any more, but this could only be confirmed with a biopsy, which is not a good idea because of the risks involved.
There have been many prayers offered up on our behalf. We have continued to trust God in everything. We believe that God has used our faith and these many prayers to sustain us and give us a peace through all of it. God has shown us that if He desires to heal me, He can do it any way He chooses using anything or anyone He chooses. We believe that God has healed me, possibly even using this new breakthrough medicine to do so. PRAISE GOD!
There is one more treatment round for me remaining in the clinical trial I am in, scheduled for the last week in February. There is a good chance that the sponsoring pharmaceutical company, Oncolytics Biotech, will want to continue treatments beyond that.
There are so many opportunities to minister to fellow cancer patients and their loved ones. We are surrounded by so many of all ages with such profound needs. At times, we feel that this is one of our biggest challenges. We need the right words to say.
Feel free to share some or all of this as you see fit. We know that God is using your website to touch many. Thank you for your prayers and concern.
Love in Christ,
Kenny and Helen Scott


Brennan's cancer battle inspires staff

When Bexley Mayor John Brennan announced in February that he had been diagnosed with pancreatic cancer, a pall fell over city council chambers. "I'm going to fight this," he said at the time. "I'm going to get through this."
Brennan has lived up to his word.
After enrolling in an aggressive, experimental treatment program at the James Cancer Center at the Ohio State University Medical Center, Brennan struggled, losing more than 30 pounds and most of his hair due to the
intensity of his treatment regimen.
"John is undergoing treatment for his cancer and has been given encouraging reports from his doctor," Masser said. "He is fulfilling his duties as mayor now, and I am confident that he will continue to do so if he is re-elected."

Brennan said he is one of a select group of patients in the United States involved in a clinical trial for the drug Reolysin, discovered in Calgary in 2005 and tested in England in 2008.

Reolysin is currently being evaluated in phase II clinical trials for treating melanoma, pancreatic, lung, ovarian, and colorectal cancers and in a phase III trial in head and neck cancer. Clinical trials have demonstrated
that Reolysin may have activity across a variety of cancer types when administered alone and in combination with other cancer therapies. "If it gets into Phase III, they could probably make it available
with the results they are having," Brennan said. "I would invest money in it. It has actually shrunk my pancreatic tumor and the liver tumor somewhat and a couple of little spots I had are gone."


Using The Common Cold To Kill Cancer

Click On Barbara Williams Picture to Watch Her Story

(Inside Science TV) – In 2013, Barbara Williams was diagnosed with stage four pancreatic cancer. She was given less than a year to live.

“I was always healthy and I didn’t think I could have it," said Williams.

More than one year later, Williams is still fighting back against cancer. She is part of a clinical trial to test a new treatment that uses a common cold virus to fight the deadly disease.

“This is one of the most promising, ah, agents I’ve seen so far in my 12 to 13 years with experience with pancreas cancer,” said Tanios Bekaii-Saab, an oncologist at the Ohio State University's Comprehensive Cancer Center in Columbus.

The treatment uses a harmless cold virus that most people have been exposed to by adulthood. When unleashed on cancer cells, the virus attacks and kills the nefarious cells leaving healthy cells unharmed.

“That virus, for whatever reason, becomes activated and starts multiplying into these cancer cells and literally kills those cancer cells from within," explained Bekaii-Saab.

When the virus is given to the patient it attaches itself to white blood cells that deliver the virus to tumors. Then, the virus infects and destroys cancer cells within the tumors, bursting the cancer cells and releasing more of the virus to attack and kill any remaining cancer cells.

“What we have so far from individual observations suggests tremendous response to this virus when added to chemotherapy,” said Bekaii-Saab.

Since starting treatment, Barbara's tumor has shrunk 49 percent, which gives her hope that she will be able to spend more time with her family.

“I’ve got one granddaughter, yeah; I want to see her grow up," said Williams.

The treatment is also being tested in patients with ovarian, lung, colon, and head and neck cancers.


Ohio State University Testing Virus Therapy To Battle Ovarian Cancer

Click On  Nancy Bennett Picture to Watch Her Story

COLUMBUS, Ohio - This is the time of year when cold and stomach virus make their way through the community.
Doctors at the Ohio State University Wexner Medical Center are using one of those viruses as medicine to change it into a cancer killer.
Inside this OSU center, Nancy Bennett is getting treated for ovarian cancer.
  The Reynoldsburg woman was diagnosed with stage 3 cancer two and a half years ago.  The diagnosis shocked her.

"It was difficult," she said.  "It was really hard.  And then everything just happened so fast after that."
Her children persuaded her to seek help at the OSU James Cancer Center.  After surgery, Bennett joined a clinical trial for a new treatment.  

It's called Reolysin.  

Doctors re-programmed a common stomach virus in a lab to fight ovarian cancer.  
The virus then seeks out the cancer cells and attacks them, while leaving healthy cells alone. Dr. David Cohn, OSU Gynecologic  Cancer Director said that he hopes the national trial not only proves Reolysin does a better job of treating patients like Bennett, but that it also makes treatment easier on them.
"We're used to traditional chemotherapy with hair loss and nausea and tiredness. This virus is very well tolerated and it's hoped that with improved treatments, that we may find that patients do better without the side effects of traditional chemotherapy," Dr. Cohn said.
"If it turns out the reo virus improves that chance of controlling the cancer, the next step would be to figure out in which patients the therapy is most effective," he said.
He said that it's a novel way to attack cancer.
Bennett is rooting for the virus to succeed.
"My hope is that it will help not just me, but lots and lots of other women, too," she said.


Reolysin in NSCLC : mode of action and clinical results

Glenwood Goss, MD,FCP(SA),FRCPC
Professor and Director, Clinical and Translational Research
The Ottawa Hospital Cancer Centre
University of Ottawa

Dr. Goss graduated from the University of Witwatersrand, Johannesburg, South Africa and completed his post-graduate training at the Royal Marsden Hospital in London, England.
He is a member of the National Cancer Institute of Canada Investigational New Drug Executive Committee and Lung Site Executive Committee.
His principal areas of research relate to lung cancer and investigation of new drugs.Dr. Goss was a founding member of the Canadian Association of Medical Oncologists (1987) and has served as president.





Local Monotherapy of REOLYSIN® for Patients with Subcutaneous Tumors

In March 2002, Oncolytics announced the final results of its completed Phase I clinical trial examining the administration of escalating dosages of REOLYSIN® directly into a subcutaneous tumor. Eighteen terminal cancer patients with progressive (actively growing) cancers that had failed to respond to conventional treatments were treated. None of the patients receiving REOLYSIN® experienced any serious adverse events related to the virus, nor were there any dose-limiting toxicities. Tumor responses were measured at both the treated lesion and remote tumor sites. Evidence of viral activity was detected in eleven of eighteen patients (61%), with tumor regression ranging from 32% to 100%. (Viral activity is defined as a transitory or lasting tumor regression of at least 30% measured in two dimensions against the tumor size prior to injection on the first day of treatment.) The primary objective of the study was to determine the safety (dose-limiting toxicity) and maximum tolerated dose of REOLYSIN®.


Best Response at Injected Lesion, Measured Against Baseline

The waterfall graph above shows the percentage of tumour regression on a per
patient basis at the lesion injected with REOLYSIN®, measured against baseline.

*Bar graph is ordered by best response at injected lesion, starting from tumour regression of 100% as shown by first two bars on far left of graph. Results do not reflect the order in which patients were treated, or the dosage received.


Reolysin shows benefit for Squamous in Phase II trial I have been keeping my eye on Reolysin and it continues to do well in multiple studies for multiple cancers.
Latest report shows shrinkage in 19 out of 20 patients. Small study but results are rather impressive to me at least.



Oncolytics lung cancer drug shrinks tumors in 95 percent patients

(Reuters) - Oncolytics Biotech Inc said a mid-stage trial of its experimental lung cancer drug showed that 95 percent of the patients experienced a reduction in the size of their tumors,


Selected Highlights

Since January 1, 2014, selected highlights announced by the Company include:

Clinical Program

Completion of patient enrollment in an ongoing, NCIC Clinical Trials Group sponsored randomized Phase II study of REOLYSIN® in patients with advanced or metastatic colorectal cancer (IND 210). The Company awaits preliminary data from this study;

Reporting completion of enrollment and interim overall and KRAS-mutated patient data from an NCI-sponsored randomized Phase II study of REOLYSIN® in combination with carboplatin and paclitaxel in patients with recurrent or metastatic pancreatic cancer (NCI-8601). The Company awaits final data from this study, which will be available once all remaining patients have progressed;

Completion of patient enrollment in an ongoing, NCI-sponsored randomized Phase II study of REOLYSIN® in combination with paclitaxel in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer (GOG-186H). The Company awaits preliminary data from this study;

Reporting final data from the Company's randomized, double-blinded clinical study examining REOLYSIN® in combination with carboplatin and paclitaxel in patients with second-line, platinum-refractory, taxane-naïve head and neck cancers;

Presentation by the Company's collaborators of preliminary clinical data demonstrating that intravenously delivered REOLYSIN® can cross the blood brain barrier to access tumours in the brains of humans;


Application for Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for REOLYSIN® in the treatment of ovarian and pancreatic cancers. The Company was granted designations in ovarian, fallopian tube, primary peritoneal and pancreatic cancer subsequent to year end;

Application to the European Medicines Agency for Orphan Designation for REOLYSIN® in the treatment of pancreatic and ovarian cancers;

Subsequent to year end, the Company applied to the U.S. FDA for a fifth Orphan Drug Designation for high grade gliomas in paediatric patients;

Basic Research

Presentation of a poster entitled "Combination Therapy with Reovirus and PD-1 Blockade Effectively Establishes Tumour Control Via Innate and Adaptive Immune Responses" by the Company's research collaborators, Vile et al., at the AACR Tumor Immunology and Immunotherapy Conference;

A series of presentations made by the Company's research collaborators at the 8th Annual International Conference on Oncolytic Virus Therapeutics held in Oxford, UK, covering:

Preclinical research examining the synergies associated with treatment in animal models with GM-CSF prior to administering REOLYSIN®;

Preclinical research focused on identifying biomarkers predictive of sensitivity/resistance to reovirus in head and neck cancer cell lines; and

Preclinical research into the treatment of hepatocellular carcinoma associated with infection by Hepatitis B and Hepatitis C;


The nomination and election of Ms. Linda Hohol and Ms. Angela Holtham to the Company's Board of Directors;


Entry into and subsequent amendments to a share purchase agreement with Lincoln Park Capital Fund, LLC;

Entry into a $20 million "At-the-Market" equity distribution agreement with Canaccord Genuity Inc.; and

At December 31, 2014 the Company reported $16.2 million in cash, cash equivalents and short-term investments.  At March 13, 2015, the Company had approximately $27.5 million in cash, cash equivalents and short-term investments.



Trial Uses Common Cold To Fight Pancreatic Cancer

A breakthrough in cancer treatment is unfolding in Central Ohio, targeting pancreatic cancer by using the common cold virus.

Pancreatic cancer has a high mortality rate. 94 percent of pancreatic cancer patients die within five years. But a new trial is using the common cold to kill cancer.

The cold virus is part of a new trial at The Ohio State University's Wexner Medical Center.

"This virus is likely to be the next standard of care in pancreas cancer," said Dr. Tanios Bekaii-Saab.

Saab is leading the charge in the first-of-its-kind trial on reolysin in pancreatic cancer.

Reolysin is the virus that causes the common cold.

"When it gets in the cancer cell, it acts in a completely different way. It's very harmful to the cancer cell, which is exactly what we want it to do," Sabb said.

Saab said the results have been amazing so far, both slowing cancer growth and reducing the size of the tumor.

It leaves healthy cells in the body alone.

It sounds too good to be true, but it's the future, and is just the beginning of virus cancer treatments unfolding currently.

"This is an oncologist's dream where you find an agent that has minimal toxicity, but when it gets to the cancer, it induces absolute harm to the cancer," Saab said.

Patients are also given chemotherapy treatment, but have fewer side effects, and are living longer with the new treatment.

CHM Cannabis
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ONCY News: Report of Foreign Issuer (6-k) 12/12/2018 02:45:54 PM
ONCY News: Oncolytics Biotech® Announces First Patient Treated in Study Combining Pelareorep, Carfilzomib and the Checkpoint Inhibitor ... 12/12/2018 07:00:00 AM
ONCY News: Report of Foreign Issuer (6-k) 12/03/2018 01:34:27 PM
ONCY News: Oncolytics Biotech® Announces Increased PD-L1 Expression When Combining Pelareorep with a Proteasome Inhibitor in Poster Pr... 12/03/2018 07:00:00 AM
ONCY News: Report of Foreign Issuer (6-k) 11/30/2018 02:03:51 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#1811   http://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aONC-2619626&symbol=ONC&region masslanding 06/06/18 01:23:54 AM
#1810   http://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aONC-2619834&symbol=ONC&region masslanding 06/05/18 01:44:28 PM
#1809   ONCYF Reverse Split 1 for 9.5 effective May TenKay 05/24/18 08:30:35 AM
#1808   Looking good here:-) Digmush 05/15/18 11:21:33 AM
#1807   https://finance.yahoo.com/news/oncolytics-biotech-r-present-microcap-144226151.h Digmush 04/04/18 11:01:33 AM
#1806   Anyone left in here??? Digmush 03/08/18 01:07:24 PM
#1805   I bowed out yesterday after holding when I Goatman75 02/02/18 09:58:31 AM
#1804   Just as I suspected >> SleighRidin'Larry 02/01/18 05:35:04 AM
#1803   Agreed..... Goatman75 01/30/18 02:44:59 PM
#1802   It wouldn't .. Unfortunately, Most Co's get the SleighRidin'Larry 01/30/18 02:43:05 PM
#1801   Why would listing on NASDAQ be possibly bad?? Goatman75 01/30/18 02:39:59 PM
#1800   News is out .. Possibly BAD .. !! SleighRidin'Larry 01/29/18 07:20:19 AM
#1799   Thanks! To whoever setup this message board, THANKS!!! gars 01/10/18 08:12:52 PM
#1798   ( ONCY ) ~ Sep 11, 2017 SleighRidin'Larry 09/11/17 07:59:57 AM
#1797   Oncolytics Biotech® Inc. Opens U.S. Based Office in SleighRidin'Larry 06/27/17 08:12:53 AM
#1796   $ONCYF offering closed and ASCO presentation this weekend deadjim 06/01/17 09:58:34 AM
#1795   http://www.investopedia.com/terms/s/shortselling.asp Noodle2 05/30/17 05:19:37 PM
#1794   Usually, when it comes to pending news, short Noodle2 05/30/17 05:15:22 PM
#1793   Exactly what bad news?? Why could the price Ad719 05/30/17 05:05:16 PM
#1792   What bad news? Noodle2 05/30/17 05:04:14 PM
#1791   Where's the bad news?? Any ideas? Ad719 05/30/17 03:39:28 PM
#1790   ONCYF buy 0.4828 stocktrademan 05/25/17 12:36:35 PM
#1789   Goatman75 05/24/17 04:10:41 PM
#1788   This closes the gap abosalman 05/24/17 01:38:00 PM
#1787   what link ? Anthropoid 05/24/17 12:08:32 PM
#1786   Click on the above link. It explains all. Goatman75 05/24/17 11:20:17 AM
#1785   Any ideas as to the drop? Ad719 05/24/17 10:28:44 AM
#1784   $2 according to Zack's Research Noodle2 05/14/17 08:07:40 AM
#1783   $1.50 Goatman75 05/09/17 12:01:04 PM
#1782   Price target? aaron_03 05/08/17 08:32:54 PM
#1781   I agree. I have been in this Goatman75 05/08/17 02:57:38 PM
#1780   Yes, I would like for it to go Noodle2 05/08/17 02:40:24 PM
#1779   Time to go North. Goatman75 05/08/17 10:44:27 AM
#1778   oncy gets fast track designation: justthefactsmam 05/08/17 08:04:39 AM
#1777   Updates from the Annual General Meeting aaron_03 05/05/17 02:05:43 AM
#1776   But I see it right track and work hard abosalman 05/04/17 05:21:34 PM
#1775   Did you listen to the conference, and if Noodle2 05/04/17 04:57:45 PM
#1774   I expect within a month abosalman 05/04/17 04:52:44 PM
#1773   Is that your prediction for close tomorrow or Noodle2 05/04/17 04:29:51 PM
#1772   $1.07 abosalman 05/04/17 01:37:23 PM
#1771   BIG DAY x 2 >>> House vote on Noodle2 05/04/17 10:20:27 AM
#1770   Have your same feeling, and feel compelled to alejrossi 05/03/17 07:16:04 PM
#1769   It appears to me that someone is not Noodle2 05/03/17 04:05:59 PM
#1768   Google Finance will have numerous articles covering Oncolytics Noodle2 05/03/17 03:54:59 PM
#1767   Just listened to Matt's presentation at the Bloom onco_investor 05/02/17 09:06:00 PM
#1766   Fully diluted into 2018 on page 27. Major Noodle2 05/02/17 08:31:33 PM
#1765   Agree. Perfect. alejrossi 05/02/17 06:44:08 PM
#1764   get the access to the audio of today's justthefactsmam 05/02/17 05:49:52 PM
#1763   Oncolytics (TSX:ONC) up nicely in Canada. Noodle2 05/02/17 05:48:02 PM
#1762   Did you read my other post about their Noodle2 05/02/17 04:45:10 PM